This preliminary study investigated the neurofunctional effects of carbamazepine-extended release (XR) treatment in 11 manic youth with bipolar disorder during performance of a sustained attention task, the Continuous Performance Task -Identical Pairs version (CPT-IP), during functional magnetic resonance imaging (fMRI). All patients underwent baseline fMRI, and 10 patients were scanned again at endpoint. Nine demographically matched healthy youth, who were scanned once, served as controls. Carbamazepine-XR treatment was associated with normalization of activation in right Brodmann area 10 (BA). These results suggest that carbamazepine-XR treatment may correct prefrontal dysfunction in adolescent mania.
Introduction
Bipolar disorder typically presents during adolescence. However, short-term studies find that only 50% of youth treated for mania respond to a given medication (Correll et al., 2010) . Therefore, additional treatment options are needed. Carbamazepine is an anti-convulsant approved by the US Food and Drug Administration for the treatment of bipolar manic or mixed episodes in adults. Several open-label studies support the safety and tolerability of carbamazepine in youth with bipolar disorder (Ginsberg, 2006) . Functional imaging studies suggest increased amygdala activation and abnormalities in ventral prefrontal function are found in youth with bipolar disorder during the performance of a task of sustained attention, and that treatment with second generation antipsychotics may correct the prefrontal alterations (Schneider et al., 2012) . To our knowledge, however, there are no published data examining the in vivo effects of extended release carbamazepine on neurofunctional activation patterns. We hypothesized that manic bipolar youth treated with carbamazepine-extended release (XR) would exhibit normalization of prefrontal and amygdala activation during a task of sustained attention.
Methods
Patients (n¼ 11) were included in this study if they (1) were 10-17 years old; (2) were diagnosed with DSM-IV-TR bipolar I disorder, current manic or mixed episode; (3) had a Young Mania Rating Scale (YMRS) scoreZ16; (4) had a Clinical Global Impressions-Severity (CGI-S) score Z4; and (5) had no prior treatment with carbamazepine. Diagnoses were confirmed using the Kiddie Schedule of Schizophrenia and Affective Disorders for School-Aged Children -Present and Lifetime Version (KSADS-PL).
Demographically matched healthy subjects (n¼ 9) were recruited from the community. Healthy subjects were free of DSM-IV-TR Axis I disorders, as confirmed by a K-SADS-PL. Subjects were eligible for participation if they had an estimated IQ 480, were free of contraindications to magnetic resonance imaging (MRI) such as braces or claustrophobia, had no major medical problems, and had no history of head trauma resulting in loss of consciousness for more than 10 min. A negative urine pregnancy test was required for girls. Before the study began and after study procedures had been explained, all study participants and their legal guardians signed written informed assent and consent, respectively. The University of Cincinnati Institutional Review Board approved this protocol.
Bipolar patients received treatment with carbamazepine-XR as part of a multicenter, 8-week, open-label study. Only patients participating at the University of Cincinnati site were eligible for the functional imaging portion of the study. Patients were initiated on a dose of 200 mg BID and titrated to a maximum tolerated dose over 5 weeks, up to 1200 mg/day. Patients underwent a washout period for any previous medications before they began the study treatment; they were taking no psychoactive medications at baseline, and no psychoactive Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/psychresns
